[1]梁婷 王慧 彭瑛.类癌综合征和类癌性心脏病的诊疗新进展[J].心血管病学进展,2021,(11):965-967,977.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
　LIANG Ting,WANG Hui,PENG Ying.Diagnosis and Treatment of Carcinoid S yndrome and Carcinoid Heart Disease[J].Advances in Cardiovascular Diseases,2021,(11):965-967,977.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
点击复制

类癌综合征和类癌性心脏病的诊疗新进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年11期
页码:
965-967,977
栏目:
综述
出版日期:
2021-11-25

文章信息/Info

Title:
Diagnosis and Treatment of Carcinoid S yndrome and Carcinoid Heart Disease
文章编号:
202101053
作者:
梁婷 王慧 彭瑛
(四川大学华西医院心内科,四川 成都 610041)
Author(s):
LIANG Ting;  WANG Hui;  PENG Ying
(Department of Cardiology,West China Hospital,Sichuan University,Chengdu 610041,Sichuan,China)
关键词:
类癌; 类癌综合征; 类癌性心脏病
Keywords:
Carcinoid; Carcinoid syndrome; Carcinoid heart disease
DOI:
10.16806/j.cnki.issn.1004-3934.2021.11.000
摘要:
类癌较为罕见，在临床中容易被误诊，其衍生的类癌综合征可出现血管舒缩、胃肠道动力增高、支气管痉挛和类癌性心脏病的改变，后者主要表现为右心瓣膜（以三尖瓣多见）开闭功能受限。多模态心血管影像学在类癌性心脏病的诊断和预后评价中扮演了重要角色。放射性核素肽受体介导治疗靶向给药，通过降低血中激素水平可有效治疗类癌综合征，同时，经导管右心瓣膜置换术也在少数类癌性心脏病患者中进行了尝试。现就类癌综合征和类癌性心脏病的诊疗新进展进行综述，以期增强临床医生对该病的认识，提供更优化的治疗途径。
Abstract:
Carcinoid is rare and easy to be misdiagnosed in clinical p ractice. Its derived carcinoid syndrome can appear changes in vasomotor contraction,increased gastrointestinal motility,bronchospasm and carcinoid heart disease. The latter is mainly characterized by limited opening and closing function of right heart valve(most commonly tricuspid valve). Multimodal cardiovascular imaging plays an important role in the diagnosis and prognosis of carcinoid heart disease. Radionuclide peptide receptor-mediated targeted therapy can effectively treat carcinoid syndrome by reducing the level of hormone in blood. At the same time,transcatheter right heart valve replacement has also been tried in a few patients with carcinoid heart disease. This paper reviews the new progress in the diagnosis and treatment of carcinoid syndrome and carcinoid heart disease, in order to enhance clinicians’ understanding of the disease and provide more optimized treatment approaches

参考文献/References:

[1].Connolly HM,Nishimura RA,Smith HC,et al. Outcome of cardiac surgery for carcinoid heart disease[J]. J Am Coll Cardiol,1995,25(2):410-416.
[2].Rindi G,Villanacci V,Ubiali A. Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors[J]. Digestion,2000,62(suppl 1):19-26.
[3].Modlin IM,Lye KD,Kidd M. A 5-decade analysis of 13,715 carcinoid tumors[J]. Cancer ,2003,97(4):934-959.
[4].Ramage JK,Ahmed A,Ardill J,et al. Guidelines for the management of gastroenteropancreatic
[5].neuroendocrine(including carcinoid) tumours(NETs)[J]. Gut,2012,61(1):6-32.
[6].Thorson A,Biorck G,Borkman G,et al. Malignant carcinoid of the small intestine with metastases to the liver,valvular disease of the right side of the heart(pulmonary stenosis and tricuspid regurgitation without septal defects),peripheral vasomotor symptoms,bronchoconstriction,and an unusual type of cyanosis:a clinical and pathologic syndrome[J]. Am Heart J,1954,47(5):795-817.
[7].Meijer WG,Kema IP,Volmer M,et al. Discriminating capacity of indole markers in the diagnosis of carcinoid tumors[J]. Clin Chem,2000,46(10):1588-1596.
[8].Soga J,Yakuwa Y,Osaka M. Carcinoid syndrome:a statistical evaluation of 748 reported cases [J]. J Exp Clin Cancer Res,1999,18(2):133-141.
[9].Pellikka PA,Tajik AJ,Khandheria BK,et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients[J]. Circulation,1993,87(4):1188-1196.
[10].Dev S,Al-Dujaily S,Subbuswamy SG. A case of ureteric obstruction,retroperitoneal fibrosis,and carcinoid tumour[J]. Postgrad Med J ,1999,75(879):38-40.
[11].Russo S,Boon JC,Kema IP,et al. Patients with carcinoid syndrome exhibit symptoms of aggressive impulse dysregulation[J]. Psychosom Med,2004,66(3):422-425.
[12].Zuetenhorst JM,Bonfrer JM,Korse CM,et al. Carcinoid heart disease:the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide,transforming growth factor-beta and fibroblast growth factor[J]. Cancer,2003,97(7):1609-1615.
[13].M?ller JE,Connolly HM,Rubin J,et al. Factors associated with progression of carcinoid heart disease[J]. N Engl J Med ,2003,348(11):1005-1015.
[14].Denney WD,Kemp WE Jr,Anthony LB,et al. Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease[J]. J Am Coll Cardiol,1998,32(4):1017-1022.
[15].Agha AM,Lopez-Mattei J,Donisan T,et al. Multimodality imaging in carcinoid heart disease[J]. Open Heart,2019,6(1):e001060.
[16].Bertin N,Favretto S,Pelizzo F,et al. Carcinoid heart disease:starting from heart failure[J]. J Investig Med High Impact Case Rep,2017,5(2):2324709617713511.
[17].Miyasaka R,Mehta A,Pettersson GB,et al. Carcinoid tricuspid valve disease:applications of three dimensional transesophageal echocardiography[J]. Circ Cardiovasc Imaging,2019(12):e009555.
[18].Pandya UH,Pellikka PA,Enriquez-Sarano M,et al. Metastatic carcinoid tumor to the heart:echocardiographic-pathologic study of 11 patients[J]. J Am Coll Cardiol ,2002,40:1328-1332.
[19].Moerman VM,Dewilde D,Hermans K. Carcinoid heart disease:typical findings on echocardiography and cardiac magnetic resonance[J]. Acta Cardiol ,2012,67(2):245-248.
[20].Gabriel M,Decristoforo C,Kendler D,et al. 68Ga-DOTATyr3-octreotide PET in neuroendocrine tumors:comparison with somatostatin receptor scintigraphy and CT[J]. J Nucl Med ,2007,48(4):508-518.
[21].Meijer WG,Copray SC,Hollema H,et al. Catecholamine-synthesizing enzymes in carcinoid tumors and pheochromocytomas[J]. Clin Chem,2003,49(4):586-593.
[22].Meijer WC,van Veldhuisen DJ,Kema IP,et al. Cardiovascular abnormalities in patients with a carcinoid syndrome[J]. Neth J Med,2002,60(1):10-16.
[23].Strobbe L,D’Hondt E,Ramboer C,et al. Ileal carcinoid tumors and intestinal ischemia[J]. Hepatogastroenterology ,1994,41(5):499-502.
[24].Larsson G,Sj?den PO,Oberg K,et al. Health-related quality of life,anxiety and depression in patients with midgut carcinoid tumours[J]. Acta Oncol,2001,40(7):825-831.
[25].Kaltsas GA,Besser GM,Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors[J]. Endocr Rev ,2004,25(3):458-511.
[26].Loughrey PB,Zhang D,Heaney AP. New treatments for the carcinoid syndrome[J]. Endocrinol Metab Clin North Am,2018,47(3):557-576.
[27].van der Horst-Schrivers AN,Wymenga AN,de Vries EG. Carcinoid heart disease[J]. N Engl J Med,2003,348(23):2359-2361.
[28].Robiolio PA,Rigolin VH,Harrison JK,et al. Predictors of outcome of tricuspid valve replacement in carcinoid heart disease[J]. Am J Cardiol,1995,75(7):485-488.
[29].Kesarwani M,Ports TA,Rao RK,et al. First-in-human transcatheter pulmonic valve implantation through a tricuspid valve bioprosthesis to treat native pulmonary valve regurgitation caused by carcinoid syndrome[J]. JACC Cardiovasc Interv,2015,8(10):e161-e163.
[30].Williams AR,Wang A,Kim H,et al. Resection of carcinoid tumor metastatic to the right ventricle and tricuspid valve[J]. Ann Thorac Surg,2015,100(6):2348-2350.
[31].M?ller JE,Pellikka PA,Bernheim AM,et al. Prognosis of carcinoid heart disease:analysis of 200 cases over two decades[J]. Circulation,2005,112(21):3320-3327.

更新日期/Last Update: 2021-12-06